Heartflow Inc

HTFL

Market cap $2.53B

Heartflow NASDAQ: HTFL reported a sharply higher first-quarter revenue total and raised its full-year 2026 outlook, citing strength in its core FFRCT business, faster-than-expected adoption of its Plaque Analysis product and continued expansion of the coronary CT angiography, or CCTA, market.

HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript

SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026.

SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 14, 2026.

Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform

HeartFlow's chief medical officer exercised 67,017 options and sold 64,533 Common Stock shares on March 19, 2026, generating proceeds of about $1.66 million at an average price around $25.69 per share. The sale represented 22.36% of Campbell's direct common stock holdings at the time of the transaction.

Capricorn Investment Group LLC bought 1,661,601 HeartFlow shares; estimated transaction value $48.18 million based on quarterly average price. The quarter-end position value increased by $48.18 million, reflecting the new share purchase.

HeartFlow delivered 40% sales growth in 2025, with revenue surpassing $176 million and strong Q4 momentum. 2026 guidance targets 25% revenue growth to $218–222 million, with gross margins rising to 80–81% and further mid-term upside to 85%. HearthFlow's AI-driven CAD diagnostic platform is gaining adoption, supported by FDA-cleared next-generation algorithms and a proprietary CT image database.

HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript

Three presentations at ACC reinforce Heartflow's AI-powered technology predicts MACE, drives superior lipid outcomes and results in cost-effective care   First patient enrolled in p ioneering N AVIGATE - PCI Registry assessing impact of Heartflow PCI Navigator on clinical strategy, efficiency and physician confidence across 5,000 patients   MOUNTAIN VIEW, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced new clinical evidence and a landmark registry launch that together advance the company's vision of transforming CAD management across every stage of the patient journey.